Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof

Abstract

The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

1 . A method of determining whether a human has an altered risk for cardiovascular disease (CVD), comprising testing nucleic acid from said human for the presence or absence of a polymorphism selected from the group consisting of the polymorphisms as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:1401-4006 and 5414 or its complement, wherein said polymorphism indicates said human has an altered risk for CVD. 
     
     
         2 . The method of  claim 1 , wherein said CVD is coronary heart disease (CHD). 
     
     
         3 . The method of  claim 2 , wherein said CHD is myocardial infarction. 
     
     
         4 . The method of  claim 1 , wherein said polymorphism is in the GOSR2 gene and wherein said CVD is hypertension. 
     
     
         5 - 10 . (canceled) 
     
     
         11 . The method of  claim 1 , wherein said testing step comprises nucleic acid amplification. 
     
     
         12 . The method of  claim 11 , wherein said nucleic acid amplification is carried out by polymerase chain reaction. 
     
     
         13 - 14 . (canceled) 
     
     
         15 . The method of  claim 1 , wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE). 
     
     
         16 . The method of  claim 1 , wherein said testing is performed using an allele-specific method. 
     
     
         17 . The method of  claim 16 , wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification. 
     
     
         18 . The method of  claim 17 , wherein said method is performed using an allele-specific primer provided in Table 5. 
     
     
         19 . (canceled) 
     
     
         20 . The method of  claim 1 , further comprising correlating the presence of said polymorphism with said human's responsiveness to a therapeutic agent. 
     
     
         21 . The method of  claim 20 , wherein said therapeutic agent comprises an HMG-CoA reductase inhibitor. 
     
     
         22 . The method of  claim 21 , wherein said polymorphism is selected from the group consisting of the polymorphisms provided in Table 22. 
     
     
         23 - 25 . (canceled) 
     
     
         26 . A method of determining whether a human will respond to an HMG-CoA reductase inhibitor for reducing risk for cardiovascular disease (CVD), comprising testing nucleic acid from said human for the presence or absence of a polymorphism selected from the group consisting of the polymorphisms provided in Table 21. 
     
     
         27 . The method of  claim 26 , further comprising administering said HMG-CoA reductase inhibitor to said human. 
     
     
         28 . (canceled) 
     
     
         29 . A method for reducing risk of cardiovascular disease (CVD) in a human, comprising administering to said human an effective amount of a therapeutic agent, said human having been identified as having an increased risk for CVD due to the presence or absence of a polymorphism selected from the group consisting of the polymorphisms as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:1401-4006 and 5414 or its complement. 
     
     
         30 . The method of  claim 29 , wherein said method comprises testing nucleic acid from said human for the presence or absence of said polymorphism. 
     
     
         31 . The method of  claim 29 , wherein said CVD is coronary heart disease (CHD). 
     
     
         32 . The method of  claim 31 , wherein said CHD is myocardial infarction. 
     
     
         33 . The method of  claim 29 , wherein said therapeutic agent comprises an HMG-CoA reductase inhibitor. 
     
     
         34 - 45 . (canceled)